Figure GPS-20. Figure GPS-20. Lifetime and last year prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country

Notes:

Data are from the most recent national surveys available in each country (see Epidemiological tables on population surveys, EMCDDA Statistical bulletin).

Countries have been sorted according to lifetime prevalence of cocaine.

In the European Member States, most surveys were conducted between 2004 and 2008, and the standard age range is 15 to 34 (in some countries the lower end may be 16 or 18 years).

The European average prevalence rate was calculated as the average of the national prevalence rates weighted by national population of 15- to 34-year olds (2006, taken from Eurostat).

In the USA, the survey was conducted in 2007, and the age range is 16 to 34 years (recalculated from original data).

In Canada, the survey was conducted in 2004, and the age range is 15 to 34 years (recalculated from original data).

For Australia, the survey was conducted in 2007, and the age range is 14 to 39 years (recalculated from original data).

Variations in age ranges may slightly influence disparities between countries.

Related links:

Statistical bulletin 2006: Figure GPS-21

Statistical bulletin 2007: Figure GPS-20

Statistical bulletin 2008: Figure GPS-20

See also Tables GPS-9

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

Reitox national reports 2008, taken from population surveys, reports or scientific articles.

Canada: Adlaf, E.M., Begin, P., and Sawka, E. (Eds.) (2005), Canadian addiction survey (CAS): ‘A national survey of Canadians' use of alcohol and other drugs: Prevalence of use and related harms: Detailed report’, Ottawa: Canadian Centre on Substance Abuse.

USA: SAMHSA, Office of Applied Studies, National survey on drug use and health, 2007.

Australian Institute of Health and Welfare 2008. 2007 National Drug Strategy Household Survey: detailed findings. Drug statistics series no. 22. Cat. no. PHE 107. Canberra: AIHW